Ticker

NewAmsterdam Pharma is advancing obicetrapib, an oral CETP inhibitor, targeting unmet LDL-C lowering needs in cardiovascular disease patients. Obicetrapib met primary and secondary endpoints in three Phase 3 trials, with significant LDL-C reductions and favorable safety, supporting regulatory filings in Europe and the US. NAMS anticipates regulatory decisions in Europe in H2 2026, with US NDA likely post-PREVAIL…

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…

NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Shineco (NASDAQ: SISI - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Institutional and Insider Ownership 89.9% of NewAmsterdam Pharma shares

Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 729,484 shares of the company's stock after purchasing an additional 67,538 shares during the period. Aberdeen Group plc owned

NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…